lestaurtinib has been researched along with Primary Myelofibrosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baer, MR; Dueck, AC; Goldberg, JD; Hexner, E; Hoffman, R; Kessler, C; Kosiorek, H; Mascarenhas, J; Pahl, H; Price, L; Sandy, L; Silverman, LR; Tremblay, D; Weinberg, R | 1 |
| Fancher, KM; Green, MR; Newton, MD | 1 |
| Baer, MR; Basu, T; Demakos, EP; Goldberg, JD; Hexner, EO; Hoffman, R; Jeschke, G; Kleczko, J; Leibowitz, D; Marchioli, R; Mascarenhas, J; Miller, C; Najfeld, V; Orazi, A; Pahl, HL; Prchal, J; Price, L; Ritchie, EK; Roboz, GJ; Silverman, LR; Siuty, J; Weinberg, R | 1 |
| Cortes, J; Estrov, Z; Garcia-Manero, G; Jain, N; Kantarjian, HM; Kennedy, D; Manshouri, T; Santos, FP; Thomas, DA; Verstovsek, S | 1 |
| Carroll, M; Hexner, EO; Jeschke, GR; Kalota, A | 1 |
1 review(s) available for lestaurtinib and Primary Myelofibrosis
| Article | Year |
|---|---|
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
3 trial(s) available for lestaurtinib and Primary Myelofibrosis
| Article | Year |
|---|---|
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.
Topics: Carbazoles; Furans; Humans; Janus Kinase 2; Janus Kinase Inhibitors; Primary Myelofibrosis; Treatment Outcome | 2019 |
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Carbazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Furans; Gastrointestinal Diseases; Humans; Janus Kinase 2; Leukopenia; Male; Middle Aged; Mutation, Missense; Primary Myelofibrosis; Treatment Outcome; Young Adult | 2015 |
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blotting, Western; Carbazoles; Cytokines; Female; Furans; Humans; Janus Kinase 2; Male; Middle Aged; Neoplasm Staging; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein-Tyrosine Kinases; Survival Rate; Thrombocythemia, Essential; Treatment Outcome | 2010 |
1 other study(ies) available for lestaurtinib and Primary Myelofibrosis
| Article | Year |
|---|---|
Intrinsic resistance to JAK2 inhibition in myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Carbazoles; Cytokines; Drug Resistance; Female; Furans; Gene Frequency; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Neutrophils; Phosphorylation; Primary Myelofibrosis; Protein Kinase Inhibitors; STAT3 Transcription Factor; STAT5 Transcription Factor | 2013 |